These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11027359)

  • 61. Erythropoietin action in stress response, tissue maintenance and metabolism.
    Zhang Y; Wang L; Dey S; Alnaeeli M; Suresh S; Rogers H; Teng R; Noguchi CT
    Int J Mol Sci; 2014 Jun; 15(6):10296-333. PubMed ID: 24918289
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Nitric oxide and hypoxia stimulate erythropoietin receptor via MAPK kinase in endothelial cells.
    Cokic BB; Cokic VP; Suresh S; Wirt S; Noguchi CT
    Microvasc Res; 2014 Mar; 92():34-40. PubMed ID: 24518819
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Presence of the Gpr179(nob5) allele in a C3H-derived transgenic mouse.
    Balmer J; Ji R; Ray TA; Selber F; Gassmann M; Peachey NS; Gregg RG; Enzmann V
    Mol Vis; 2013; 19():2615-25. PubMed ID: 24415894
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Erythropoietin has a restorative effect on the contractility of arteries following experimental hypoxia.
    Withers SB; Passi N; Williams AS; de Freitas D; Heagerty AM
    J Cardiovasc Dis Res; 2013 Sep; 4(3):164-9. PubMed ID: 24396255
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Decreased stability of erythroblastic islands in integrin β3-deficient mice.
    Wang Z; Vogel O; Kuhn G; Gassmann M; Vogel J
    Physiol Rep; 2013 Jul; 1(2):e00018. PubMed ID: 24303107
    [TBL] [Abstract][Full Text] [Related]  

  • 66. PPARα and Sirt1 mediate erythropoietin action in increasing metabolic activity and browning of white adipocytes to protect against obesity and metabolic disorders.
    Wang L; Teng R; Di L; Rogers H; Wu H; Kopp JB; Noguchi CT
    Diabetes; 2013 Dec; 62(12):4122-31. PubMed ID: 23990359
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Erythropoietin contributes to slow oxidative muscle fiber specification via PGC-1α and AMPK activation.
    Wang L; Jia Y; Rogers H; Suzuki N; Gassmann M; Wang Q; McPherron AC; Kopp JB; Yamamoto M; Noguchi CT
    Int J Biochem Cell Biol; 2013 Jul; 45(7):1155-64. PubMed ID: 23523698
    [TBL] [Abstract][Full Text] [Related]  

  • 68. HIF-1α is a protective factor in conditional PHD2-deficient mice suffering from severe HIF-2α-induced excessive erythropoiesis.
    Franke K; Kalucka J; Mamlouk S; Singh RP; Muschter A; Weidemann A; Iyengar V; Jahn S; Wieczorek K; Geiger K; Muders M; Sykes AM; Poitz DM; Ripich T; Otto T; Bergmann S; Breier G; Baretton G; Fong GH; Greaves DR; Bornstein S; Chavakis T; Fandrey J; Gassmann M; Wielockx B
    Blood; 2013 Feb; 121(8):1436-45. PubMed ID: 23264599
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Red blood cell volume and the capacity for exercise at moderate to high altitude.
    Jacobs RA; Lundby C; Robach P; Gassmann M
    Sports Med; 2012 Aug; 42(8):643-63. PubMed ID: 22741918
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Endogenous erythropoietin signaling facilitates skeletal muscle repair and recovery following pharmacologically induced damage.
    Jia Y; Suzuki N; Yamamoto M; Gassmann M; Noguchi CT
    FASEB J; 2012 Jul; 26(7):2847-58. PubMed ID: 22490927
    [TBL] [Abstract][Full Text] [Related]  

  • 71. High-altitude diving in river otters: coping with combined hypoxic stresses.
    Crait JR; Prange HD; Marshall NA; Harlow HJ; Cotton CJ; Ben-David M
    J Exp Biol; 2012 Jan; 215(Pt 2):256-63. PubMed ID: 22189769
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Erythropoietin in the intensive care unit: beyond treatment of anemia.
    Patel NS; Collino M; Yaqoob MM; Thiemermann C
    Ann Intensive Care; 2011 Sep; 1():40. PubMed ID: 21943500
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Excessive erythrocytosis compromises the blood-endothelium interface in erythropoietin-overexpressing mice.
    Richter V; Savery MD; Gassmann M; Baum O; Damiano ER; Pries AR
    J Physiol; 2011 Nov; 589(Pt 21):5181-92. PubMed ID: 21859826
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Flow-mediated vasodilation in end-stage renal disease.
    Verbeke FH; Pannier B; Guérin AP; Boutouyrie P; Laurent S; London GM
    Clin J Am Soc Nephrol; 2011 Aug; 6(8):2009-15. PubMed ID: 21784831
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Acute erythropoietin cardioprotection is mediated by endothelial response.
    Teng R; Calvert JW; Sibmooh N; Piknova B; Suzuki N; Sun J; Martinez K; Yamamoto M; Schechter AN; Lefer DJ; Noguchi CT
    Basic Res Cardiol; 2011 May; 106(3):343-54. PubMed ID: 21347618
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Erythropoietic and non-erythropoietic functions of erythropoietin in mouse models.
    Vogel J; Gassmann M
    J Physiol; 2011 Mar; 589(Pt 6):1259-64. PubMed ID: 21282290
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Exercise aggravates cardiovascular risks and mortality in rats with disrupted nitric oxide pathway and treated with recombinant human erythropoietin.
    Meziri F; Binda D; Touati S; Pellegrin M; Berthelot A; Touyz RM; Laurant P
    Eur J Appl Physiol; 2011 Aug; 111(8):1929-38. PubMed ID: 21249387
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Interdialytic hypertension-an update.
    Agarwal R
    Adv Chronic Kidney Dis; 2011 Jan; 18(1):11-6. PubMed ID: 21224025
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Cardiovascular effects of erythropoietin an update.
    Santhanam AV; d'Uscio LV; Katusic ZS
    Adv Pharmacol; 2010; 60():257-85. PubMed ID: 21081221
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Macrophages as novel target cells for erythropoietin.
    Lifshitz L; Tabak G; Gassmann M; Mittelman M; Neumann D
    Haematologica; 2010 Nov; 95(11):1823-31. PubMed ID: 20595096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.